ATE414515T1 - Medikamente zur gleichzeitigen erhöhung der analgetischen wirksamkeit und verminderung des abhängigkeitspotentials, die durch exogene und endogene opioidagonisten verursacht werden - Google Patents
Medikamente zur gleichzeitigen erhöhung der analgetischen wirksamkeit und verminderung des abhängigkeitspotentials, die durch exogene und endogene opioidagonisten verursacht werdenInfo
- Publication number
- ATE414515T1 ATE414515T1 AT05008904T AT05008904T ATE414515T1 AT E414515 T1 ATE414515 T1 AT E414515T1 AT 05008904 T AT05008904 T AT 05008904T AT 05008904 T AT05008904 T AT 05008904T AT E414515 T1 ATE414515 T1 AT E414515T1
- Authority
- AT
- Austria
- Prior art keywords
- bimodally
- excitatory
- opioid receptor
- acting
- opioid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/276,966 US5512578A (en) | 1992-09-21 | 1994-07-19 | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE414515T1 true ATE414515T1 (de) | 2008-12-15 |
Family
ID=23058858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05008904T ATE414515T1 (de) | 1994-07-19 | 1995-07-18 | Medikamente zur gleichzeitigen erhöhung der analgetischen wirksamkeit und verminderung des abhängigkeitspotentials, die durch exogene und endogene opioidagonisten verursacht werden |
Country Status (8)
Country | Link |
---|---|
US (1) | US5512578A (de) |
EP (2) | EP0808165A4 (de) |
JP (2) | JPH10507740A (de) |
AT (1) | ATE414515T1 (de) |
AU (2) | AU3276995A (de) |
CA (1) | CA2195122A1 (de) |
DE (1) | DE69535890D1 (de) |
WO (1) | WO1996002251A1 (de) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5316759A (en) * | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
US6096756A (en) * | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US6673558B1 (en) | 1992-09-30 | 2004-01-06 | Richard G. Lanzara | Drug compositions to prevent desensitization of cellular receptors |
US6406866B1 (en) | 1993-11-08 | 2002-06-18 | Oregon Health Sciences University | Method of screening of a compound for binding to MSOR |
US5834477A (en) * | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
US5821219A (en) * | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
US5760044A (en) * | 1996-05-16 | 1998-06-02 | Archer; Sydney | Method for treating cocaine and amphetamine dependency |
AU3499997A (en) * | 1996-06-24 | 1998-01-14 | Rockefeller University, The | Method of using ligands of the kappa opioid receptor |
US6153621A (en) * | 1997-06-23 | 2000-11-28 | The University Of Kentucky Research Foundation | Combined antagonist compositions |
US5965567A (en) * | 1997-07-15 | 1999-10-12 | Albany Medical College | Method for treating nicotine addiction |
US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6559158B1 (en) * | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
TR200001828T2 (tr) | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem. |
CN1234362C (zh) * | 1997-12-22 | 2006-01-04 | 欧罗赛铁克股份有限公司 | 阿片样激动剂/阿片样拮抗剂组合物 |
AU2003200858B2 (en) * | 1997-12-22 | 2005-04-07 | Euro-Celtique S.A. | A Method of Preventing Abuse of Opioid Dosage Forms |
US6375957B1 (en) * | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
US6194382B1 (en) * | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
US6541021B1 (en) * | 1999-03-18 | 2003-04-01 | Durect Corporation | Devices and methods for pain management |
US6835194B2 (en) * | 1999-03-18 | 2004-12-28 | Durect Corporation | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
US6765010B2 (en) * | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
EP1255547B1 (de) | 2000-02-08 | 2008-08-20 | Euro-Celtique S.A. | Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten |
EP2092936B1 (de) | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Missbrauchssichere orale Opioidagonisten-Formulierungen |
US7074803B2 (en) * | 2001-03-02 | 2006-07-11 | Durect Corporation | Opioid formulations |
WO2001085257A2 (en) * | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
US20040024004A1 (en) * | 2001-05-04 | 2004-02-05 | Sherman Barry M. | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
CA2408098A1 (en) * | 2000-05-05 | 2001-11-15 | Pain Therapeutics, Inc. | Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists |
CA2411564A1 (en) * | 2000-06-09 | 2001-12-13 | The Regents Of The University Of California | Method of treating pain using nalbuphine and opioid antagonists |
JP2004528273A (ja) * | 2000-10-30 | 2004-09-16 | ペイン・セラピューティクス・インコーポレイテッド | 血液脳関門でのabc薬物トランスポーターのインヒビター |
ITMI20010907A1 (it) * | 2001-05-02 | 2002-11-02 | Valpharma Sa | Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi |
CA2778114A1 (en) * | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
ATE493130T1 (de) | 2001-05-11 | 2011-01-15 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
EP1404323B1 (de) * | 2001-06-05 | 2009-10-28 | The University of Chicago | Verwendung von methylnaltrexon zur behandlung von immunsuppression |
EP1406629A1 (de) * | 2001-07-02 | 2004-04-14 | Omeros Corporation | Verfahren zur induzierung von analgesie beinhaltend die verabreichung alternativ eines opiat-rezeptoragonists und eines opiat-rezeptor ähnlichen-1 rezeptoragonists und eine implantierbare infusionspumpe |
US20030040479A1 (en) * | 2001-07-02 | 2003-02-27 | Omeros Corporation | Rotational intrathecal analgesia method and device |
ATE376832T1 (de) * | 2001-07-06 | 2007-11-15 | Penwest Pharmaceuticals Co | Verzögert freisetzende formulierungen von oxymorphon |
CN1268338C (zh) * | 2001-07-06 | 2006-08-09 | 恩德制药公司 | 用作止痛剂的6-羟基羟吗啡酮的口服给药 |
US8329216B2 (en) * | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
EP1416842B1 (de) * | 2001-07-18 | 2008-12-31 | Euro-Celtique S.A. | Pharmazeutische kombinationen von oxycodon und naloxon |
MXPA04001210A (es) | 2001-08-06 | 2004-07-08 | Euro Celtique Sa | Formulaciones de agonista opioide con antagonista liberable y aislado. |
US20030044458A1 (en) * | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
US20030157168A1 (en) * | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
DE10142996A1 (de) * | 2001-09-01 | 2003-03-27 | Paz Arzneimittelentwicklung | Verwendung von Wirkstoffen mit mu-Opioid-Rezeptor agonistischer Wirkung als Kombinationsarzneimittel zur Krebsbehandlung |
CA2459976A1 (en) * | 2001-09-26 | 2003-04-03 | Penwest Pharmaceuticals Company | Opioid formulations having reduced potential for abuse |
US6458795B1 (en) * | 2001-11-15 | 2002-10-01 | University Of Florida | Method and composition for treatment of irritable bowel disease |
EP1476155A4 (de) * | 2002-01-23 | 2009-10-28 | Univ California | Verfahren und zusammensetzungen zur verringerung der entstehung von arzneimitteltoleranz und/oder physischer abhängigkeit |
US20060177381A1 (en) * | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
EP2289492B1 (de) | 2002-03-14 | 2016-12-07 | Euro-Celtique S.A. | Naltrexonhydrochloridzusammensetzungen |
LT2425821T (lt) | 2002-04-05 | 2017-07-25 | Euro-Celtique S.A. | Farmacinis preparatas, turintis oksikodono ir naloksono |
WO2004026283A1 (en) | 2002-09-20 | 2004-04-01 | Alpharma, Inc. | Sequestering subunit and related compositions and metohds |
US20040102476A1 (en) * | 2002-11-25 | 2004-05-27 | Chan Tai Wah | High concentration formulations of opioids and opioid derivatives |
US20040110781A1 (en) * | 2002-12-05 | 2004-06-10 | Harmon Troy M. | Pharmaceutical compositions containing indistinguishable drug components |
WO2004054511A2 (en) * | 2002-12-13 | 2004-07-01 | The Regents Of The University Of California | Analgesic combination comprising nalbuphine |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
PT2368553E (pt) * | 2003-04-08 | 2015-03-03 | Progenics Pharm Inc | Formulações farmacêuticas contendo metilnaltrexona |
WO2004091665A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
US20050004155A1 (en) * | 2003-04-08 | 2005-01-06 | Boyd Thomas A. | Use of methylnaltrexone to treat irritable bowel syndrome |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
EP1604666A1 (de) * | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit |
JP2008528497A (ja) * | 2005-01-20 | 2008-07-31 | プロジェニックス ファーマシューティカルズ,インコーポレーテッド | メチルナルトレキソンおよび関連化合物の術後性胃腸障害のための使用 |
EP1702558A1 (de) * | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
CN104248763A (zh) * | 2005-03-07 | 2014-12-31 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
AU2006287070A1 (en) * | 2005-08-30 | 2007-03-08 | Queen's University At Kingston | Potentiation of the therapeutic action of an opioid receptor agonist and/or inhibition or reversal of tolerance to an opioid receptoi agonists using an ultralow dose of an alpha-2 receptor antagonist |
US20070212414A1 (en) * | 2006-03-08 | 2007-09-13 | Penwest Pharmaceuticals Co. | Ethanol-resistant sustained release formulations |
AU2007238625A1 (en) * | 2006-04-14 | 2007-10-25 | Shire Llc | Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse |
US8158156B2 (en) * | 2006-06-19 | 2012-04-17 | Alpharma Pharmaceuticals, Llc | Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist |
WO2008008380A1 (en) * | 2006-07-12 | 2008-01-17 | Regents Of The University Of Minnesota | Combination therapy for addiction disorders |
EP1897543A1 (de) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine-Waffel zur Substitutionstherapie |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
CN101657101B (zh) * | 2007-02-12 | 2013-12-11 | Dmi生物科学公司 | 并存早泄和勃起功能障碍的治疗 |
EP2114147B9 (de) * | 2007-02-12 | 2013-04-10 | DMI Biosciences, Inc. | Verringerung der nebenwirkungen von tramadol |
PE20090700A1 (es) * | 2007-03-29 | 2009-07-13 | Progenics Pharm Inc | Compuestos heterociclicos como antagonistas del receptor opioide periferico |
CA2865389A1 (en) * | 2007-03-29 | 2008-10-09 | Progenics Pharmaceuticals, Inc. | Crystal forms and uses thereof |
EP2139890B1 (de) | 2007-03-29 | 2014-06-25 | Wyeth LLC | Peripherer opioid-rezeptor antagonisten und verwendungen davon |
US20090124650A1 (en) * | 2007-06-21 | 2009-05-14 | Endo Pharmaceuticals, Inc. | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol |
US8883817B2 (en) * | 2007-10-18 | 2014-11-11 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US20100151014A1 (en) * | 2008-12-16 | 2010-06-17 | Alpharma Pharmaceuticals, Llc | Pharmaceutical composition |
EP2224808A4 (de) * | 2007-12-17 | 2013-11-27 | Alpharma Pharmaceuticals Llc | Pharmazeutische zusammensetzung |
CN101959892B (zh) | 2008-02-06 | 2014-01-08 | 普罗热尼奇制药公司 | (r),(r)-2,2’-二-甲基纳曲酮的制备和用途 |
JP5647098B2 (ja) | 2008-03-21 | 2014-12-24 | ザ ユニヴァーシティー オヴ シカゴ | オピオイド拮抗薬とmTOR阻害薬を用いた治療 |
MY150600A (en) * | 2008-07-07 | 2014-01-30 | Euro Celtique Sa | Use of opioid antagonists for treating urinary retention |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US20100227876A1 (en) * | 2009-03-06 | 2010-09-09 | Rechfensen Llp | Methods of Reducing Side Effects of Analgesics |
US9271940B2 (en) | 2009-03-10 | 2016-03-01 | Purdue Pharma L.P. | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
IT1398930B1 (it) | 2010-03-24 | 2013-03-28 | Molteni & C | Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi. |
CA2868413C (en) | 2012-04-17 | 2021-07-20 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
WO2015011189A1 (en) | 2013-07-23 | 2015-01-29 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
FR3032353B1 (fr) | 2015-02-06 | 2017-03-10 | Jacques Seguin | Composition pharmaceutique et dispositif pour le traitement de la douleur |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4457933A (en) * | 1980-01-24 | 1984-07-03 | Bristol-Myers Company | Prevention of analgesic abuse |
US4361553A (en) * | 1981-05-18 | 1982-11-30 | Regents Of The University Of California | Therapeutic uses of dynorphin |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4889860A (en) * | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US4760069A (en) * | 1985-09-23 | 1988-07-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
JPH0653683B2 (ja) * | 1988-07-14 | 1994-07-20 | ザ ロックフェラー ユニバーシティ | 慢性痛あるいは慢性咳を治療する経口用組成物 |
EP0352361A1 (de) * | 1988-07-29 | 1990-01-31 | The Rockefeller University | Verfahren zur Behandlung von Patienten die an chronischen Schmerzen oder chronischem Husten leiden |
JPH03163030A (ja) * | 1989-08-28 | 1991-07-15 | Arizona Technol Dev Corp | アヘン剤活性を選択的に強化し、アヘン剤耐性と依存性を軽減するための組成物と方法 |
US5075341A (en) * | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
HU208633B (en) * | 1991-02-04 | 1993-12-28 | Alkaloida Vegyeszeti Gyar | Process for production of analgetic compositions as applicable for blocking of opioid-binding spaces /2-receptors/ causing respiration depression |
US5352680A (en) * | 1992-07-15 | 1994-10-04 | Regents Of The University Of Minnesota | Delta opioid receptor antagonists to block opioid agonist tolerance and dependence |
EP0668764A1 (de) * | 1992-09-21 | 1995-08-30 | QIN, Bo-yi | Verfahren zur identifikation und verwendung von opioidanalgetika mit niedrigem bzw. ohne abhängigkeitspotential |
US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US5321012A (en) * | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
-
1994
- 1994-07-19 US US08/276,966 patent/US5512578A/en not_active Ceased
-
1995
- 1995-07-18 CA CA002195122A patent/CA2195122A1/en not_active Abandoned
- 1995-07-18 EP EP95929400A patent/EP0808165A4/de not_active Withdrawn
- 1995-07-18 AU AU32769/95A patent/AU3276995A/en not_active Abandoned
- 1995-07-18 AT AT05008904T patent/ATE414515T1/de not_active IP Right Cessation
- 1995-07-18 WO PCT/US1995/009974 patent/WO1996002251A1/en not_active Application Discontinuation
- 1995-07-18 DE DE69535890T patent/DE69535890D1/de not_active Expired - Fee Related
- 1995-07-18 EP EP05008904A patent/EP1600160B1/de not_active Expired - Lifetime
- 1995-07-18 JP JP8505298A patent/JPH10507740A/ja active Pending
-
1999
- 1999-07-26 AU AU41135/99A patent/AU4113599A/en not_active Abandoned
-
2008
- 2008-09-18 JP JP2008239858A patent/JP2009062376A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0808165A1 (de) | 1997-11-26 |
EP0808165A4 (de) | 1999-11-24 |
DE69535890D1 (de) | 2009-01-02 |
JP2009062376A (ja) | 2009-03-26 |
EP1600160A1 (de) | 2005-11-30 |
AU3276995A (en) | 1996-02-16 |
WO1996002251A1 (en) | 1996-02-01 |
AU4113599A (en) | 1999-09-23 |
US5512578A (en) | 1996-04-30 |
EP1600160B1 (de) | 2008-11-19 |
CA2195122A1 (en) | 1996-02-01 |
JPH10507740A (ja) | 1998-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE414515T1 (de) | Medikamente zur gleichzeitigen erhöhung der analgetischen wirksamkeit und verminderung des abhängigkeitspotentials, die durch exogene und endogene opioidagonisten verursacht werden | |
Thongpradichote et al. | Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-admintstered mitragynine in mice | |
Schulz et al. | Supersensitivity to opioids following the chronic blockade of endorphin action by naloxone | |
Mellon et al. | Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism (s) of action | |
ATE388707T1 (de) | Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen | |
Noda et al. | Opiate physical dependence and N-methyl-D-aspartate receptors | |
IL142921A0 (en) | USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS | |
CA2379524A1 (en) | Salts and bases of the 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opiod analgesics | |
Narita et al. | Effects of κ-agonist on the antinociception and locomotor enhancing action induced by morphine in mice | |
Archer et al. | Cyclazocine revisited | |
NO980700D0 (no) | Perifert aktive anti-hyperalgesi opiater | |
DE69525847T2 (de) | Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit | |
ATE446751T1 (de) | Verwendung von methylnaltrexon zur behandlung von immunsuppression | |
WO2002076388A3 (en) | Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside | |
AU4130196A (en) | Methods of treating migraine | |
Finn et al. | Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, D-amphetamine, and methylphenidate | |
Nozaki et al. | Characterization of the antinociceptive effects of oxycodone in diabetic mice | |
Holtman Jr et al. | Sex-related differences in the enhancement of morphine antinociception by NMDA receptor antagonists in rats | |
Weinstock | Acetylcholine and cholinesterase | |
Kaneko et al. | Intracerebroventricular administration of angiotensin II attenuates morphine-induced analgesia in mice | |
Van Bockstaele et al. | Elevated μ‐opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs after chronic low dose naltrexone in opiate‐dependent rats | |
Drago et al. | Amphetamine-induced analgesia does not involve brain opioids | |
Briggs et al. | Kappa antinociceptive activity of spiradoline in the cold-water tail-flick assay in rats | |
Crain et al. | Etorphine elicits unique inhibitory-agonist and excitatory-antagonist actions at opioid receptors on sensory neurons: New rationale for improved clinical analgesia and treatment of opiate addiction | |
Bhargava et al. | Effects of naltrexone on the binding of [3H] D-Ala2, MePhe4, Gly-ol5-enkephalin to brain regions and spinal cord and pharmacological responses to morphine in the rat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |